Welcome to our dedicated page for AKTIS ONCOLOGY SEC filings (Ticker: AKTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to aggregate U.S. regulatory filings for Aktis Oncology, Inc. (Nasdaq: AKTS), a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors. While specific SEC filings are not listed in the provided information, a Nasdaq-listed issuer such as Aktis Oncology would typically use SEC reports to describe its business, pipeline, risks, and capital structure in more detail.
Annual and quarterly reports, such as Forms 10-K and 10-Q when available, generally provide narrative and financial disclosure about companies like Aktis Oncology. For a clinical-stage radiopharmaceutical company, these documents often include descriptions of its miniprotein radioconjugate platform, targeted tumor types, clinical development plans, and factors that could affect its research and development activities.
Registration statements, such as the Form S-1 that Aktis Oncology reports was declared effective in connection with its initial public offering, offer additional background on the company’s history, founding, and the structure of its capital raising transactions. Aktis Oncology has stated that its common stock began trading on the Nasdaq Global Select Market under the ticker AKTS following the effectiveness of its Form S-1.
On this filings page, Stock Titan’s tools can be used to review such documents when they are available from the SEC’s EDGAR system. AI-powered summaries are designed to highlight key sections of lengthy filings, such as business descriptions, risk factors related to clinical development and radiopharmaceutical safety, and disclosures about collaborations like the company’s strategic relationship with Eli Lilly and Company.
Users interested in AKTS can use this page to monitor new filings as they appear, compare successive disclosures, and better understand how Aktis Oncology presents its radiopharmaceutical platform, pipeline candidates, and single operating segment focused on research and development in official regulatory documents.
Aktis Oncology director Ken Herrmann filed an initial Form 3 reporting his beneficial ownership in the company mainly through stock options to buy common stock.
The filing lists six stock option grants with exercise prices from $0.08 to $18.00 per share and expiration dates between November 23, 2030 and January 7, 2036. Options covering 6,571 and 19,714 shares have vested in full, while other grants, including 26,285, 64,399 and 10,514 underlying shares, vest in monthly installments tied to his continuous service. A grant covering 18,933 shares is scheduled to vest in full on January 8, 2027. All reported options are held directly.
Aktis Oncology, Inc. reported initial insider holdings by investment entities associated with MPM Bioimpact. The filing shows indirect beneficial ownership of 341,709 shares of Common Stock and indirect holdings of preferred stock that can convert into Common Stock. These include 1,314,262 shares of Series Seed Redeemable Convertible Preferred Stock, 5,914,197 shares of Series A Redeemable Convertible Preferred Stock, and 1,577,119 shares of Series B Redeemable Convertible Preferred Stock, all held indirectly through funds and entities such as MPM Asset Management LLC and various MPM BioVentures and Oncology funds.
Each share of the Series Seed, Series A and Series B preferred stock is convertible into Common Stock on a 3.8044-for-1 basis, and these preferred shares will convert into Common Stock upon the closing of the company’s initial public offering. The reporting persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest.
Aktis Oncology director Lloyd Mitchell Segal filed an initial Form 3 reporting his equity interests as of January 8, 2026. Indirect holdings include 13,142 shares of Series A Redeemable Convertible Preferred Stock and 6,489 shares of Series B Redeemable Convertible Preferred Stock held by Arvala, Inc., where he is president and sole stockholder and may share voting and dispositive power. Each preferred share is convertible into common stock on a 3.8044-for-1 basis and will automatically convert to common stock immediately before the closing of Aktis Oncology’s initial public offering. He also reports several stock options for common stock, including grants covering 32,856, 31,542, 6,571, 10,514 and 18,933 shares at exercise prices ranging from $1.45 to $18.00, with one grant fully vested and others vesting monthly or in full on January 8, 2027 subject to continued service.
Aktis Oncology, Inc. (AKTS) filed an initial insider ownership report for President and CEO, and director, Matthew Roden as of January 8, 2026. He directly beneficially owns 91,998 shares of common stock and holds several stock option awards. These include options to purchase 578,277 shares at $1.91 per share that have fully vested, as well as options for 558,095 shares at $3.66, 618,757 shares at $9.33, and 394,280 shares at $18 per share, which vest over time according to specified schedules tied to his continued service with the company.
Aktis Oncology, Inc. had several MPM-affiliated investment vehicles file an initial Form 3 to report their beneficial ownership as of 01/08/2026. The group reports indirect ownership of 341,709 shares of common stock and indirect holdings of Series Seed, Series A and Series B Redeemable Convertible Preferred Stock, which are each convertible into common stock on a 3.8044-for-1 basis. The preferred shares will convert into common stock upon the closing of Aktis Oncology’s initial public offering and have no expiration date. The reporting persons state that they disclaim beneficial ownership of these securities except to the extent of their pecuniary interest, and the shares are held through various MPM-managed funds and entities.
Aktis Oncology Chief Operating Officer Shulamit Ron-Bigger reported her existing stock option holdings in a Form 3 insider ownership filing. The filing lists stock options to purchase 267,888 shares of common stock at $3.66 per share expiring on 10/30/2032, 18,697 shares at $4.95 expiring on 06/30/2034, 118,284 shares at $9.33 expiring on 10/10/2034, and 131,426 shares at $18 expiring on 01/07/2036, all held directly.
For three grants, 25% of the original option amount either has vested or is scheduled to vest on specific dates, with the remaining portions vesting in equal monthly installments over 48 months, as long as Ron-Bigger continues in service. This filing establishes her baseline equity position as an officer of Aktis Oncology.
Aktis Oncology director and 10% owner Todd Foley filed a Form 3 detailing his indirect and direct interests in the company’s securities as of January 8, 2026. Investment entities associated with him hold 597,391 shares of Series Seed Redeemable Convertible Preferred Stock, 2,688,270 shares of Series A Redeemable Convertible Preferred Stock, and 716,872 shares of Series B Redeemable Convertible Preferred Stock, each series convertible into common stock on a 3.8044‑for‑1 basis upon the closing of the company’s initial public offering. Foley disclaims beneficial ownership of these preferred shares except to the extent of his pecuniary interest. He also directly holds a stock option for 37,866 shares of common stock at an exercise price of $18 per share, vesting in equal monthly installments over 36 months starting January 8, 2026, conditioned on continued service.
Aktis Oncology, Inc. filed an initial Form 3 showing that its Chief Scientific Officer, Paul L. Feldman, beneficially owns 144,568 shares of common stock directly as of January 8, 2026.
He also holds several stock options to buy common stock: one option for 65,713 shares at an exercise price of $1.91 per share expiring on April 14, 2031, which has vested in full; an option for 119,248 shares at $3.66 per share expiring on November 15, 2032 that vests monthly after 25% vested on November 1, 2023; an option for 90,684 shares at $9.33 per share expiring on October 10, 2034 with similar monthly vesting after 25% vested on October 9, 2025; and an option for 131,246 shares at $18 per share expiring on January 7, 2036, with 25% scheduled to vest on January 8, 2027 and the remainder in monthly installments, all subject to his continuous service.
Aktis Oncology, Inc. Chief Medical Officer Akos Czibere filed an initial ownership report showing holdings of several stock options. These options give rights to buy common stock at exercise prices of $4.95 for 271,218 shares, $9.33 for 98,570 shares, $11.46 for 19,714 shares, and $18.00 for 131,426 shares, all held directly. Portions of the earlier grants vested on July 1, 2025 and October 9, 2025, with the remaining shares vesting in equal monthly installments, subject to continued service. Newer grants are scheduled to begin vesting with 25% cliffs on November 1, 2026 and January 8, 2027, followed by monthly vesting thereafter.
Aktis Oncology director Michael A. Sherman filed a report of his beneficial ownership of stock options in Aktis Oncology, Inc. On January 8, 2026, he held a stock option for 74,913 shares of common stock at an exercise price of $9.14, expiring on October 8, 2035. Twenty‑five percent of these shares vest on August 1, 2026, with the remainder vesting in equal monthly installments, subject to his continued service. He also held a second stock option for 18,933 shares at an exercise price of $18, expiring on January 7, 2036, which vests in full on January 8, 2027 if he remains in service.